Medesthetics

MAY-JUN 2016

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: https://medesthetics.epubxp.com/i/668890

Contents of this Issue

Navigation

Page 53 of 71

52 MAY/JUNE 2016 | Med Esthetics NEWS & EVENTS AAD ANNOUNCES NEW OFFICERS The American Academy of Dermatology (AAD) announced its new offi cers at the conclusion of its 74 th Annual Meeting in March. Abel Torres, MD, JD, FAAD, a Cleveland-based derma- tologist and lawyer, took offi ce as president. He will hold offi ce for one year. Dr. Torres earned his medical degree from the Mount Sinai School of Medicine in New York City. He completed his residency in internal medicine at Loma Linda University Medical Center (LLUSM) in Loma Linda, California, his residency in dermatology at the New York University School of Medicine in New York City, and his fellowship in advanced dermatologic surgery and Mohs surgery at the University of California, San Francisco. Dr. Torres is a professor and chairman of the department of dermatology at Case Western Reserve University MetroHealth Systems in Cleveland, professor and chairman of the department of dermatology at LLUSM, and an associate professor of public health at Loma Linda University. In addition, Dr. Torres received his JD degree from Loyola Marymount University in Los Angeles and is a member of the California Bar. Currently, Dr. Torres is a member of the AAD's Board of Directors and past treasurer for the American Society for Dermatologic Surgery (ASDS). "I am honored to serve the AAD at a time when there are a number of important issues facing our specialty," said Dr. Torres. "Strengthening the sense of community among dermatologists and our patients can turn these challenges into opportunities and enhance the quality of patient care." Kenneth J. Tomecki, MD, FAAD, begins a one-year term as vice president of the AAD. Dr. Tomecki is a Brooklyn native and graduate of the Columbia College of Physicians and Surgeons. He is also a clini- cal staff physician in the department of dermatology at the Cleveland Clinic, a board member of the International Society of Dermatology, a member of the AAD's Board of Directors and executive committee, and a past secretary and trustee of the Ohio Derm Association. Four physicians were appointed to the AAD's Board of Directors. They include: Erin E. Boh, MD, PhD, FAAD, Kimberly J. Butterwick, MD, FAAD, Neil S. Sadick, MD, FAAD, and Linda Stein Gold, MD, FAAD. They will each serve four-year terms. BIOPHARMX COMMENCES BPX-01 STUDY Specialty pharmaceutical company BioPharmX has announced that it will immediately initiate a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic topical formulation of minocycline. The study will assess the drug's effectiveness in reducing the number of acne-causing bacteria in patients at four weeks as well as evaluate its safety and tolerability. The company's preclinical studies have found that BPX-01 can deliver the antibiotic to the layer of skin where the acneic condi- tion develops while minimizing systemic exposure. The unique minocycline gel is designed to distribute evenly without occluding or irritating the skin. "We are excited to begin our IND study of BPX-01," said Kin F. Chan, PhD, executive vice president of research and development at BioPharmX. "Our nonclinical research has been well received by the dermatology community." GALDERMA INITIATES TWO PHASE 3 RESTYLANE TRIALS Galderma will be launching two pivotal Phase 3 trials focused on its Restylane dermal fi llers. The Restylane Silk Cannula Study is a multicenter trial that will evaluate the safety and tolerability of Restylane Silk when delivered via microcannula. The Restylane Lyft Hand Rejuvenation Study is a random- ized, controlled, multicenter study to assess the safety, tolerability and effi cacy of Restylane Lyft for volume loss in the hands. For more information, visit galderma.com. ENVY MEDICAL APPOINTS NEW CEO Arash Khazei has joined Envy Medical as its new CEO, replacing Curtis Cluff. Prior to working at Envy Medical, Khazei held an SVP position at L'Oreal, managing the fi nancial operation and integra- tion of NYX Cosmetics subsequent to its acquisition by L'Oreal in 2014. "It's a privilege to join the seasoned team at Envy Medical," said Khazei. "I look forward to applying past successful experiences to support Envy's robust growth strategy while continuing to position the company as a pioneer and leader in face and body medical treat- ments and skin care." ZELTIQ LAUNCHES THREE-IN-ONE COOLADVANTAGE APPLICATOR ZELTIQ Aesthetics has launched a new family of applicators called CoolAdvantage for use with its CoolSculpting noninvasive fat reduction system. The applicators feature an adaptable three-in-one confi guration and enhanced cup design to deliver cooling technology at a lower temperature, cutting treatment time nearly in half. The shape of the applicator cup increases direct tissue contact to deliver results in just 35 minutes. A clinical study conducted by Suzanne Kilmer, MD, that compared the CoolAdvantage enhance- ments to the commercially available CoolCore applicator demon- strated equivalent fat layer reduction measured by ultrasound and blinded photographic review. The new applicator cup shape led to a 45% increase in comfort during the treatment and 85% of study subjects preferred the CoolAdvantage treatment due to its decreased treatment time and increased comfort. The adaptable three-in-one applicator includes: • CoolFit Advantage for vertical areas of fat such as the inner thigh. Abel Torres, MD, JD

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - MAY-JUN 2016